Trial reportJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2017
Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial.
Trial report in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 67 citations in OpenAlex.
- Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial.Lancet (London, England) · 2023Trial
- Case Report: Serial stereotactic radiotherapy in lieu of systemic therapy change for oligoprogressive breast cancer: eight courses to 17 metastases.Frontiers in oncology · 2026Article
- Stereotactic ablative radiotherapy-driven immunosuppression is associated with poorer progression-free survival in cancer patients.Cancer immunology, immunotherapy : CII · 2025Article
- Leucine-rich repeat-containing G protein-coupled receptor 4 promotes proliferation, invasion and migration, and inhibits apoptosis in non-small cell lung cancer cells.Oncology letters · 2025Article
- Prognostic factors after radical local therapy for oligo-recurrence of non-small cell lung cancer.General thoracic and cardiovascular surgery · 2025Article
- Reirradiation - still navigating uncharted waters?Clinical and translational radiation oncology · 2024Review
- STRILL: Phase I Trial Evaluating Stereotactic Body Radiotherapy (SBRT) Dose Escalation for Re-Irradiation of Inoperable Peripheral Lung Lesions.Diseases (Basel, Switzerland) · 2024Article
- The relationship between splenic dose and radiation-induced lymphopenia.Journal of radiation research · 2024Article
- Novel prognostic signature for lung adenocarcinoma based on immune-related mRNA pairs.Heliyon · 2024Article
- Re-irradiation for intra-thoracic tumours and extra-thoracic breast cancer: dose accumulation, evaluation of efficacy and toxicity based on a literature review.The British journal of radiology · 2022Review
- Outcomes of SBRT for lung oligo-recurrence of non-small cell lung cancer: a retrospective analysis.Journal of radiation research · 2022Article
- Treatment outcomes of re-irradiation using stereotactic ablative radiotherapy to lung: a propensity score matching analysis.Radiation oncology (London, England) · 2021Article
- Revisiting the formalism of equivalent uniform dose based on the linear-quadratic and universal survival curve models in high-dose stereotactic body radiotherapy.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2021Article
- Developments in radiation techniques for thoracic malignancies.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- Late Central Airway Toxicity after High-Dose Radiotherapy: Clinical Outcomes and a Proposed Bronchoscopic Classification.Cancers · 2021Article
- Stereotactic ablative radiotherapy as single treatment for early stage non-small cell lung cancer: A single institution analysis.Thoracic cancer · 2021Article
- Target volume definition for staple line recurrences of non-small cell lung cancer.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2021Article
- Clinical Outcomes and Prognostic Factors of Salvage Stereotactic Body Radiotherapy for Post-Surgical Thoracic Oligo-Recurrence/Metastasis of Non-Small-Cell Lung Cancer.Cancer management and research · 2021Article
- Survival Outcomes of Salvage Therapy for Local and Regionally Recurrent NSCLC.JTO clinical and research reports · 2020Article
- Characteristics of surgically resected non-small cell lung cancer patients with post-recurrence cure.Thoracic cancer · 2020Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
15 authors at 1 institution in 1 country.
Funding
Abstract
objectivesOur goal was to evaluate stereotactic ablative radiotherapy (SABR) as a salvage option for isolated recurrence of NSCLC in the lung parenchyma after definitive treatment of stage I to III disease.
methodsPatients who had histologically confirmed, positron emission tomography-staged, isolated NSCLC recurring locally or metastasis in the lung parenchyma (≤3 cm, suitable for SABR) after previous definitive treatment were prospectively enrolled in this trial and treated with volumetric, image-guided SABR to 50 Gy in four fractions. Patients were then followed with computed tomography or positron emission tomography/computed tomography. Primary end points included the pattern of failure after salvage SABR, overall survival (OS), and progression-free survival (PFS).
resultsFifty-nine patients with recurrent disease were treated with salvage SABR. The median age was 70 years (range 45-86 years), and the median follow-up time after salvage SABR was 58.3 months. Re-recurrence after salvage SABR developed in 19 patients (32%). Measuring from the date of salvage SABR, the estimated 5-year rates of local, regional, and distant failure were 5.2%, 10.3%, and 22.4%, respectively; the estimated PFS was 46.2% at 3 years and 41.1% at 5 years; and the OS rates were 63.5% at 3 years and 56.5% at 5 years. A high post-SABR neutrophil-to-lymphocyte ratio was found to predict poor survival. Grade 3 treatment-related adverse events developed in three patients (5%). No patient had a grade 4 or 5 event.
conclusionOur study showed that salvage SABR provides excellent 5-year OS, local control, and PFS rates with minimal toxicity for patients with isolated NSCLC recurrence in the lung parenchyma. These results are striking and comparable to historically reported outcomes of patients with primary early-stage NSCLC treated with definitive SABR. SABR appears to be a very effective and safe salvage option for patients with isolated lung parenchyma recurrent disease after definitive treatment and should be considered along with surgery as a potential first-line option for patients with local lung parenchymal recurrent disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.